CEO Robert Ford made his first purchase of company stock since March.

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott Laboratories ended the fourth quarter with sales growth below Wall Street’s expectations, driven primarily by ongoing ...

Abbott's Medical Devices segment, especially CGM, continues to deliver robust double-digit growth, offsetting Nutrition ...

Abbott Laboratories (ABT) is back in focus after its fourth quarter 2025 earnings, where revenue of US$11.46b missed Wall ...

The medical-products maker’s shares tumbled after its quarterly profit and sales underwhelmed investors.

Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

That downside risk was realized by Abbott Laboratories (NYSE:ABT) shareholders over the last year, as the share price ...

The consensus rating for Abbott Laboratories is Outperform, based on 3 analyst ratings. With an average one-year price target ...

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

In recent weeks, Abbott Laboratories raised its quarterly dividend for the 52nd consecutive year and secured CE Mark approval ...

ADJUSTED EARNINGS: Stripping out certain one-time items, earnings are forecast to come in at $1.50 a share. That compares with adjusted earnings of $1.34 a share a year earlier. REVENUE: Quarterly ...